Home › Bell Radar › ATTO

ATTOAttovia Therapeutics

US ExchangeHealth Care2026-08-05

Clinical-stage biopharma developing biparatopic biologics (ATTOBODY platform) for immune-mediated pruritic diseases.

$17IPO price
$289MRaised
$21.9Day-1 close
0.82%Day-1 return
Clinical-stage biopharma developing biparatopic biologics (ATTOBODY platform) for immune-mediated pruritic diseases.
Company description (source: StockAnalysis)

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobuli...

医疗健康生物医药免疫学
51CFO read: CFO requires CMC cost modeling, rare-disease commercial readiness planning, and platform-technology valuation expertise.
Management details per the SEC prospectus.
Company profile SEC prospectus
Does your company need this kind of CFO?

51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.

Talk to us